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Abstract
The wnt signal transduction pathway is involved in many differentiation events during embryonic development and can
lead to tumor formation after aberrant activation of its components. The cytoplasmic component L-catenin is central to the
transmission of wnt signals to the nucleus: in the absence of wnts L-catenin is constitutively degraded in proteasomes,
whereas in the presence of wnts L-catenin is stabilized and associates with HMG box transcription factors of the LEF/TCF
family. In tumors, L-catenin degradation is blocked by mutations of the tumor suppressor gene APC (adenomatous polyposis
coli), or of L-catenin itself. As a consequence, constitutive TCF/L-catenin complexes are formed and activate oncogenic
target genes. This review discusses the mechanisms that silence the pathway in cells that do not receive a wnt signal and goes
on to describe the regulatory steps involved in the activation of the pathway. ß 2000 Elsevier Science B.V. All rights
reserved.
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1. Introduction
1.1. Overview of the wnt pathway
Wnts constitute a family of secreted glycoproteins
with distinct expression patterns in the embryo and
in the adult organism. Wnts appear to be involved in
di¡erentiation processes by controlling embryonic in-
duction, polarity of cell division, cell fate and growth
[1]. A role for wnts in tumorigenesis was ¢rst sug-
gested by the identi¢cation of the mouse wnt-1 (int-
1) (proto-)oncogene, which is frequently activated by
insertion of the mouse mammary tumor virus. In
Xenopus embryos ectopic expression of wnts can in-
duce the formation of a secondary body axis, result-
ing in double-headed tadpoles, a phenomenon re-
lated to the capacity of the wnt pathway to induce
dorsalization of the embryo. This Xenopus ‘double
axis assay’ is frequently used to study the activity
and hierarchy of wnt signaling components [2]. Ho-
mologs of wnts are also found in non-vertebrate spe-
cies. In Drosophila, the homologous wingless path-
way is involved in the establishment of segment
polarity, wing formation and di¡erentiation of the
endoderm [1]. In Caenorhabditis elegans ¢ve wnt-
like ligands have been identi¢ed by sequence. Best
characterized so far is mom-2 (‘more mesoderm’),
which is involved in cell fate speci¢cation in the early
embryo [3].
The wnt signal transduction pathway has been an-
alyzed through a combination of genetic and bio-
chemical approaches. It was shown to involve essen-
tially similar components in vertebrates, Drosophila
and C. elegans and a common picture of wnt signal-
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ing has emerged [4]. We will shortly summarize the
main features of the pathway and give an overview
of the molecular characteristics of the involved fac-
tors. The biochemical relationships of the compo-
nents will then be discussed in more detail in the
following sections.
Wnts mainly act on target cells in a paracrine fash-
ion through members of the frizzled receptor family
of seven transmembrane spanning proteins [5]. Bind-
ing of wnts occurs at an N-terminal cysteine-rich
extracellular domain and leads to activation of the
receptors by an unknown mechanism. It is still un-
clear how the signal is further transmitted from the
receptor into the cytoplasm, but the C-terminal cy-
toplasmic domain and the cytoplasmic loops which
connect the transmembrane domains are likely to
interact with signaling molecules yet to be discov-
ered. Frizzleds were ¢rst discovered in Drosophila,
but a number of vertebrate homologs with distinct
expression patterns have been described. The rela-
tionship between these and the di¡erent wnt ligands
is only beginning to be analyzed.
A number of factors that a¡ect the wnt-frizzled
interaction have been identi¢ed (Fig. 1). The porcu-
pine gene product is a transmembrane protein local-
ized in the endoplasmic reticulum and is required for
secretion of wingless in Drosophila [6]. Homologs of
porcupine also exist in mammalian species, but their
function with regard to wnt activity has not been
reported. The GPI-linked heparan sulfate proteogly-
can dally was shown to cooperate with frizzled, pos-
sibly by acting as a co-receptor for wingless [7,8].
Several other extracellular proteins have been shown
to interact with wnts and prevent binding to friz-
zleds. Among these are cerberus [9], WIF-1 (wnt-in-
teracting factor) [10], and secreted frzB receptors re-
lated to the cysteine-rich wnt binding domain of
frizzleds (also called sFRPs, secreted frizzled-related
proteins). These antagonize the wnt pathway by
competing with frizzled receptors for wnts [11^13].
The secreted factor dickkopf-1 (Dkk-1) was also
shown to block wnt activity, but it is not known
whether it physically interacts with wnts [14,15].
Activated frizzled receptors induce the stabiliza-
tion of the cytoplasmic component L-catenin by
blocking the function of a multiprotein L-catenin de-
struction complex (Fig. 1; for references see the fol-
lowing sections). This complex consists of the scaf-
folding component axin, or the related conductin
(also named axil). These bind to the tumor suppres-
sor protein adenomatous polyposis coli (APC), the
serine/threonine kinase GSK3L (glycogen synthase
kinase 3L, zeste-white3/shaggy in Drosophila) and
L-catenin through separate domains. In the absence
of a wnt signal, GSK3L mediates the phosphoryla-
tion of L-catenin which is then recognized by the F-
box protein slimb/LTrCP and the ubiquitination ma-
chinery, and ¢nally degraded in proteasomes (Fig. 1,
‘3wnt’). In the presence of wnt, the cytoplasmic
phosphoprotein dishevelled is activated and inter-
feres with the L-catenin destruction complex.
GSK3L activity is inhibited, and the phosphorylation
of L-catenin is blocked. The activity of GSK3L may
be suppressed by binding to GBP (GSK3L binding
protein)/Frat1 (frequently rearranged in advanced T-
cell lymphomas), which can also interact with di-
shevelled. The activity of the L-catenin destruction
complex may also be regulated by dephosphoryla-
tion, as subunits of protein phosphatase 2A have
been shown to bind both axin and APC. Hypophos-
phorylated L-catenin is no longer degraded and ac-
cumulates in the cytoplasm and the nucleus, where it
associates with transcription factors of the LEF-1/
TCF family (LEF-1, TCF-1, -3 and -4; below collec-
tively referred to as TCF). The TCF/L-catenin com-
plexes act as transcriptional activators of wnt target
genes and transmit the wnt signal into the nucleus
(Fig. 1).
The transcriptional activity of the TCF/L-catenin
complexes can be modulated by di¡erent means (Fig.
1; for references see the following sections). A
MAPK-related pathway involving TAK1 (TGFL-ac-
tivated kinase) and NLK (NEMO-like kinase) phos-
phorylates the TCF/L-catenin complex and interferes
with its binding to DNA. Wnt target genes can also
be silenced by the interaction of TCFs with tran-
scriptional co-repressors such as TLE/groucho family
members and CtBP. In Drosophila the histone acetyl-
transferase CBP/p300 was shown to acetylate TCF,
which reduces the interaction with L-catenin. Fur-
thermore L-catenin binds to other nuclear factors,
such as the Drosophila zinc ¢nger protein teashirt,
or the TATA binding protein TBP.
Wnt signaling might also be in£uenced by the cad-
herin-based cell adhesion system. L-Catenin associ-
ates with the cytoplasmic domain of cadherins [16],
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and binds the vinculin-related protein K-catenin,
which in turn makes contact to actin ¢laments [17].
L-Catenin has a core domain of 12 so-called arm
repeats [18] and binding of this region to cadherins
and TCF factors is mutually exclusive [19]. Overex-
pression of the transmembrane and cytoplasmic do-
mains of cadherins blocks axis formation in Xenopus
embryos [20], and TCF/L-catenin mediated transcrip-
tion in cell culture [19], presumably by depleting the
cytoplasmic (signaling) pool of L-catenin. On the
Fig. 1. Overview of the wnt pathway. Binding of wnts to frizzled receptors activates dishevelled which blocks the function of a com-
plex assembled over the sca¡old proteins axin or conductin. Note that axin and conductin are related proteins that can form similar
complexes with APC, GSK3L, L-catenin, and PP2A and that APC can interact independently with L-catenin. In the absence of wnts
(3wnt) the axin/conductin complexes promote phosphorylation of L-catenin by GSK3L. Phosphorylated L-catenin becomes multi-ubiq-
uitinated (Ub) and subsequently degraded in proteasomes. In the presence of wnts phosphorylation and degradation of L-catenin is
blocked which allows the association of L-catenin with TCF transcription factors (+wnt). The TCF/L-catenin complexes bind to DNA
and activate wnt target genes. Additional regulatory factors that alter the activity of wnts or of downstream components and the com-
plex of L-catenin with cadherins and K-catenin are also shown. For details refer to the text.
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other hand, studies in Drosophila show that the func-
tions of L-catenin in cell adhesion and signaling can
be completely separated: certain mutations of the L-
catenin homolog armadillo only block cell adhesion,
but do not a¡ect wingless signaling, and armadillo
mutants have been generated that lack signaling ac-
tivity, but still function in cell adhesion [21]. Simi-
larly, mutant L-catenin proteins defective in cell ad-
hesion can still elicit a wnt signal in Xenopus, i.e.
induce a secondary body axis [20]. The question re-
mains whether cadherins are physiological regulators
of wnt signaling. Conversely it has been suggested
that wnt signaling regulates cadherin-based cell ad-
hesion by altering the levels of L-catenin [22].
1.2. Wnt signaling in normal development
The in vivo function of wnt family members has
been extensively investigated in C. elegans, Drosophi-
la, zebra¢sh, Xenopus, chicken, and mice. We will
here concentrate on the mouse system; several excel-
lent reviews cover the results from other organisms
[3,4,23^25]. Wnts are expressed in a tissue-speci¢c
manner, and mutant mice with deletion of certain
wnt genes display strong phenotypes. For example,
the lack of wnt-1 results in the deletion of part of the
midbrain [26], and ablation of the wnt-4 and wnt-7a
genes a¡ects kidney and limb development, respec-
tively [27,28]. Wnt-3 knockout mice are de¢cient in
the formation of the anterior-posterior axis [29]. In-
terestingly, mutations in one of the mouse dishev-
elled homologs, Dvl-1, have no gross e¡ects on em-
bryonal development but lead to behavioral
abnormalities in the adult [30]. Several studies sug-
gest a role of the wnt pathway in epithelial-mesen-
chymal interactions during development. The knock-
out of the LEF-1 gene results in defects in the
formation of teeth, hair follicles and the mammary
gland, organs known to require inductive interac-
tions of the epithelium with the underlying mesen-
chyme [31]. Transgenic mice that express LEF-1 in
keratinocytes show alterations in hair follicle pattern-
ing [32], and transgenic overexpression of a domi-
nant-active version of L-catenin in the skin induces
the formation of additional hair follicles and results
in hair follicle tumors [33]. The mutation of TCF-4
leads to abnormalities in the epithelium of the small
intestine. In these mice, the stem cell compartment in
the prospective crypts is missing, indicating that
TCF-4/L-catenin signaling is required for continued
proliferation of crypt cells [34]. The TCF-1 knockout
is characterized by a block in the development of T-
cells [35]. Somewhat astonishingly, the TCF null phe-
notypes described so far do not mimic known wnt
mutations. However, mice double-de¢cient for LEF-
1 and TCF-1 exhibit defects in the formation of par-
axial mesoderm and develop additional neural tubes,
a phenotype also seen in wnt3a-de¢cient mice [36].
This indicates that TCFs can have redundant roles in
wnt signaling during mouse development.
1.3. Wnt signaling in cancer
Several lines of evidence demonstrate a role of the
wnt signaling pathway and the TCF/L-catenin inter-
action in cancer. Certain wnts are found to be over-
expressed in tumor samples (e.g. [37]) and a subset
can transform cultured breast epithelial cells [38], but
a causal role for wnts in the development of human
cancer has not been established. In contrast, down-
stream components of the wnt pathway clearly play a
fundamental role in tumor development. Increased
nuclear staining of L-catenin and constitutive com-
plexes with TCFs are frequently observed in tumor
cell lines and tissue samples [39^42]. Stabilization of
L-catenin in tumors results from mutations of the
APC tumor suppressor, or of L-catenin itself
[41,43]. Most human colorectal cancers are initiated
by mutations of APC, which behaves as a classic
tumor suppressor and shows loss of heterozygosity
in the earliest recognizable benign tumors [44]. For
this reason APC has been proposed to act as a gate-
keeper for colonic epithelial cell proliferation. A
causal relationship between the loss of APC and de-
velopment of colorectal tumors has been con¢rmed
in mice. Mice heterozygous for APC develop tumors
in the intestinal tract, which show loss of hetero-
zygosity for the APC gene [45,46], and conditional
targeted mutation of APC in the mouse colon indu-
ces the formation of polyps, which progress to inva-
sive carcinomas [47].
In colorectal tumors that lack mutations in APC,
activating mutations of L-catenin have been identi-
¢ed. These mutations alter or delete critical serine
and threonine phosphorylation sites in the amino-
terminal domain of L-catenin that are required for
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degradation [41]. While mutations of APC are
mainly found in colorectal cancer, mutations of
L-catenin have been found in a wide variety of tumor
types, indicating a potent role for L-catenin as an
oncogene in vivo (for review see [48]). On a cellular
level, APC and L-catenin mutations correlate with
increased amounts of cytosolic and nuclear L-catenin
and transcriptionally active TCF/L-catenin com-
plexes [41,49]. This results in the inappropriate acti-
vation of TCF target genes, including c-myc and
cyclinD1 [50,51], which may ultimately lead to can-
cer. Furthermore, TCF/L-catenin complexes were
shown to have transforming activity in some cell
types [52,53]. In mice transgenic expression of a dom-
inant-active L-catenin in the skin induces the forma-
tion of hair follicle tumors [33]. Interestingly, knock-
out mice de¢cient for TCF-1 were recently shown to
develop adenomas in the gut and the mammary
glands and additional mutation of APC increases
the number of adenomas [54]. This indicates that
TCF-1 acts as a repressor of oncogenic target genes
in the absence of activated L-catenin (possibly
through interaction with grouchos, see below), and
that depletion of TCF-1 in the knockout animal re-
sults in the relieve of this repression and cellular
transformation. Moreover, TCF-1 and APC may co-
operate in tumor suppression [54].
2. The OFF state of the wnt pathway
Given the deleterious consequences of inappropri-
ate activation of the wnt pathway, organisms have
evolved several mechanisms to keep in check e¡ec-
tors of the pathway in the absence of a wnt signal.
Free L-catenin levels are kept low by a multiprotein
destruction complex that targets L-catenin to the
proteasome. In addition TCF target genes can be
silenced by transcriptional co-repressors that bind
TCFs, or by posttranslational modi¢cations of
TCF/L-catenin complexes.
2.1. The L-catenin destruction complex
While L-catenin bound to cadherins is apparently
quite stable, the cytosolic pool of L-catenin has a
short half-life in the absence of a wnt signal. Its
destruction is initiated by the action of a multipro-
tein complex which is assembled by the core compo-
nents axin or conductin/axil. Axin or conductin can
simultaneously bind to APC, L-catenin and GSK3L
[55^60]. The complex promotes the GSK3L-depen-
dent phosphorylation of L-catenin, which targets it
for multi-ubiquitination and degradation by the pro-
teasome.
Axin was identi¢ed as the gene mutated in the
Fused mouse strains, of which certain alleles are re-
cessive embryonic lethal and cause ‘Siamese’ axis du-
plications [61^63]. In Xenopus embryos, ectopic
expression of axin prevents formation of the
endogenous, and also of a wnt-induced secondary
axis [63]. Mouse conductin and its rat ortholog axil
were isolated as interaction partners of L-catenin and
GSK3L, respectively [55,60]. Axin and conductin
show 45% identity in their amino acid sequence
[55,63,64] and appear to be functionally interchange-
able. They consist of an amino-terminal ‘regulator of
G-protein signaling’ (RGS) domain which binds to
APC [55,56,64], separate binding domains for
GSK3L and L-catenin in the center of the proteins
Fig. 2. Schematic representation of the structure of mouse axin. Amino acid numbering is according to [63]. The RGS domain, the
DIX domain, and a 36 amino acid insert that is present in form 2 of axin are shown by boxes. Domains in axin interacting with
APC [64], GSK3L [80], L-catenin [57], axin [65], and mouse Dishevelled-1 (Dvl-1 [109]) are indicated by brackets. Note that Dvl-1 can
interact at two sites with axin [109].
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[55,57,59], and a C-terminal (DIX) domain related to
a segment of dishevelled, which mediates dimeriza-
tion of axin (Fig. 2) [57,63,65,66]. When overex-
pressed in mammalian cells, axin and conductin
promote the degradation of cytosolic L-catenin
[55,56,64], prevent the wnt-induced accumulation of
L-catenin [67], and transcription of a TCF-dependent
reporter gene [59,65]. The apparent lack of enzymatic
function and the direct interaction of axin family
members with L-catenin, GSK3L and APC suggest
that they function as sca¡olds that enhance the ac-
tivity of the complex by assembling the components
in close proximity. Consistent with this view, axin
stimulates the phosphorylation of L-catenin and
APC by GSK3L [56,57,68].
APC appears to be a crucial component of the
L-catenin destruction complex. In colon tumors, mu-
tations of APC correlate with high levels of L-catenin
and transcriptionally active TCF/L-catenin com-
plexes. The re-introduction of wild-type APC into
colorectal cancer cells reduces L-catenin levels [69],
and antagonizes TCF/L-catenin-mediated transcrip-
tion [49], con¢rming that APC negatively controls
L-catenin stability. Several studies also suggest this
function of APC during normal development. In
Drosophila, inactivation of an APC homolog, which
is mainly expressed in neuronal cells [70], results in
TCF/L-catenin-mediated loss of photoreceptor cells
by apoptosis [71]. A second Drosophila APC gene
is expressed ubiquitously with particularly high levels
in epithelial cells, and was named E-APC. Consistent
with a role for E-APC in antagonizing the wnt path-
way, dsRNA interference with E-APC results in phe-
notypes resembling ectopic wnt signaling. Interest-
ingly, E-APC localizes to E-cadherin and L-catenin-
containing adherens junctions and this localization
pattern depends on GSK3L function [72]. While the
above studies are compatible with the model that
APC antagonizes wnt signaling by reducing L-cate-
nin levels, not all experimental systems allow the
same conclusion. In C. elegans, the null phenotype
of an APC homolog mimics the loss of wnt or
L-catenin function [73], and overexpression of APC
in Xenopus embryos mimics wnt-induced axis dupli-
cation [74]. Both results suggest that APC may also
be involved in the transmission of wnt signals.
APC contains heptad repeats at its N-terminus
that mediate homo-oligomerization, and seven arma-
dillo repeats of unknown function (Fig. 3). The C-
terminal part contains a basic domain that binds
microtubules, a region interacting with EB1, and a
domain that binds the human homolog of the Dro-
sophila discs-large protein (DLG) [75]. The central
part of APC contains three 15 amino acid, and seven
20 amino acid repeats that both bind L-catenin [75].
Interspersed within the 20 amino acid repeat region
of APC are three so-called SAMP repeats that have
been shown to mediate the interaction with conduc-
tin and, by inference, axin [55]. In colorectal cancer
cells, the 20 amino acid repeat region was shown to
be su⁄cient to downregulate L-catenin [69]. In addi-
tion, the vast majority of mutations in APC occur in
this region and result in C-terminally truncated APC
proteins that in most cases still retain 20 amino acid
repeats and bind to L-catenin, but lack all SAMP
repeats. This suggests that the interaction with axin
or conductin is required for APC to function as a
tumor suppressor and that both proteins must coop-
erate to mediate the degradation of L-catenin. In-
deed, knockout mice of APC that retain the N-ter-
minal part including one SAMP repeat, but lack all
the C-terminal domains do not show any signs of
tumor formation [76]. In addition, expression of
APC fragments containing the SAMP repeats results
in the stabilization of L-catenin, presumably by in-
terfering with the association of endogenous APC
with conductin and axin [55]. Surprisingly, axin and
conductin are capable of degrading L-catenin when
overexpressed in cells that lack functional APC
[55,56]. This indicates that axin and conductin can
also function downstream from or independently of
APC. On the other hand, conductin is expressed in
colorectal cancer cells that lack functional APC (J.
Behrens, unpublished observations), but is obviously
not su⁄cient to control the high levels of L-catenin.
It is likely that under physiological conditions the
interaction of APC and axin/conductin is required
for the degradation of L-catenin, while under condi-
tions of overexpression axin or conductin are su⁄-
cient for degradation. It is not yet understood which
essential function APC contributes to the destruction
complex.
Another critical component of the L-catenin de-
struction complex is the serine/threonine kinase
GSK3L that has multiple functions within the cell.
In both Drosophila and Xenopus, interference with
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GSK3L function is su⁄cient to induce phenotypes
characteristic for wnt signaling [77^79]. Conversely,
ectopic overexpression of GSK3L prevents axis for-
mation in Xenopus [78], and TCF-dependent reporter
gene activation in mammalian cells [80]. Genetic evi-
dence in Drosophila suggests that in the absence of a
wnt signal, GSK3L antagonizes downstream ele-
ments of the wnt pathway by negatively regulating
the levels of L-catenin [77]. GSK3L can phosphory-
late speci¢c serine and threonine residues in the N-
terminus of L-catenin in vitro [79] and mutation of
these sites results in the stabilization of L-catenin
[41,79,81,82], suggesting that phosphorylation of
L-catenin by GSK3L at these sites targets it for
degradation. L-Catenin is generally not a good sub-
strate for GSK3L in vitro, but is e⁄ciently phos-
phorylated in the presence of axin [57].
Phosphorylated L-catenin is a target for multi-
ubiquitination and degradation by the 26S protea-
some (for review see [83]). Proteasome inhibitors sta-
bilize L-catenin and promote the accumulation of L-
catenin-ubiquitin complexes. Ubiquitination is pre-
vented by wnt signaling, by treatment of cells with
the GSK3L inhibitor LiCl, or by point mutations of
the N-terminal phosphorylation sites in L-catenin
[81,84]. The formation of ubiquitin-protein conju-
gates involves an enzymatic cascade of ubiquitin
transfer reactions. In an ATP-dependent reaction,
ubiquitin is ¢rst attached to a ubiquitin-activating
enzyme (E1), then transferred to a ubiquitin-conju-
gating enzyme (E2), which cooperates with an E3
component to join ubiquitin to a lysine residue of
the target protein. Multi-ubiquitinated proteins are
recognized by the regulatory subunit of the protea-
some and immediately degraded into short peptides.
The substrate speci¢city of the ubiquitination machi-
nery is determined by a large number of E3s [85].
Phosphorylated L-catenin is recognized by the E3
component slimb, which was identi¢ed in Drosophila
[86]. The slimb phenotype mimics constitutive activa-
tion of the wnt pathway, indicating that slimb neg-
atively regulates wnt signaling. Indeed, slimb mutant
£ies accumulate high levels of armadillo [86]. Slimb is
highly homologous to Xenopus LTrCP and contains
an F-box and seven WD40 repeats. In Xenopus, co-
expression of LTrCP prevents formation of a wnt-
induced secondary axis and a dominant-negative
LTrCP lacking the F-box induces a secondary axis
[87]. In mammalian cells, the overexpression of
slimb/LTrCP enhances the ubiquitination of L-cate-
nin, while a dominant-negative slimb/LTrCP lacking
the F-box prevents ubiquitination and stabilizes
L-catenin [88]. The WD40 repeat domain of slimb/
LTrCP speci¢cally recognizes phosphorylated L-cat-
enin while the F-box recruits the general ubiquitina-
tion machinery into the complex [89]. The role of
slimb/LTrCP in L-catenin degradation suggests that
it might be a tumor suppressor; however, a prelimi-
Fig. 3. Domain structure of APC and interaction with binding partners. The domains of APC are described in the text. The interac-
tion of the 15 aa acid repeats and the 20 aa repeats with L-catenin and of the SAMP repeats with axin/conductin is indicated by ar-
rows. The interaction of EB1 and dlg1 at the C-terminus of APC is also indicated (see text for details).
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nary analysis of four colon cancers wild-type for
APC and L-catenin did not reveal mutations in
slimb/LTrCP [90].
2.2. Transcriptional co-repressors silence TCF target
genes
In the absence of wnt signals, tight control of
L-catenin levels prevent its association with TCF
and the transcription of wnt target genes. In ad-
dition, these genes can be actively repressed by the
recruitment of transcriptional co-repressors to DNA-
bound TCFs (for review see [25,91]).
TCFs bind to members of the TLE/groucho family
of co-repressors [92^94], and coexpression of TLE/
groucho with TCF inhibits transcription of a TCF-
dependent reporter gene, even in the presence of
L-catenin [92,93]. In Xenopus, TCF-3 can also medi-
ate repression by binding to the transcriptional co-
repressor CtBP (C-terminal binding protein) [95]. Ge-
netic experiments in C. elegans and Drosophila sug-
gest that the interaction of TCFs with co-repressors
is of physiological importance. In C. elegans, loss-of-
function mutations in POP-1, a TCF homolog, show
a phenotype resembling constitutive wnt signaling,
suggesting that POP-1 acts as a transcriptional re-
pressor [73,96]. That TCFs mediate repression is fur-
ther indicated by the ¢nding that in Drosophila, a
reduction in gene dosage of TCF, or loss of function
of groucho, suppresses the phenotype of wingless or
armadillo mutations, presumably by de-repressing
wingless target genes [94].
2.3. Posttranslational modi¢cations antagonize TCF
activity
In Drosophila TCF was shown to interact with
CREB binding protein (CBP/p300) [97]. CBP has
been shown to act as a transcriptional co-activator
in a variety of settings, in which it presumably alters
chromatin structure by virtue of its histone acetylase
activity. Surprisingly, in the context of TCF, CBP
acts as a transcriptional co-repressor. As expected
for a repressor, loss-of-function mutations of CBP
suppress wingless and armadillo phenotypes. The
mechanism by which CBP inhibits TCF function is
not entirely clear, but CBP has been shown to ace-
tylate a speci¢c lysine residue in the armadillo bind-
ing domain of TCF. This modi¢cation reduces the
interaction of TCF with armadillo [97].
TCF/L-catenin complexes can be phosphorylated
by a MAPK-related pathway, which prevents their
binding to DNA. In C. elegans, homologs of
TAK1 (TGFL activated kinase-1), a MAP-kinase-
kinase-kinase family member, and of NLK
(NEMO-like kinase), a member of the MAP-kinase
family [98,99], were shown to be required for the
downregulation of TCF activity. In Xenopus, ectopic
expression of NLK blocks formation of the endoge-
nous axis, and prevents the formation of a L-catenin-
induced secondary axis [100]. In mammalian cells
NLK also inhibits L-catenin-stimulated TCF reporter
gene activity [100]. At least in C. elegans, L-catenin
interacts directly with NLK and can stimulate its
kinase activity [99]. This leads to the phosphoryla-
tion of TCF and its relocalization from the nucleus
to the cytoplasm [99]. In bandshift assays, NLK re-
duces binding of TCF/L-catenin complexes to DNA.
NLK is apparently activated by the kinase TAK1
and its binding protein TAB1. Coexpression of
TAB1 and TAK1 stimulates the kinase activity of
NLK and inhibits the transcriptional activation of
a TCF reporter gene by L-catenin [100]. Genetic evi-
dence in C. elegans also suggests that TAB1 is in-
volved in the inhibition of TCF activity upstream of
TAK1 [98]. The physiological role of this pathway is
best documented in C. elegans, where it cooperates
with wnt signaling in the establishment of posterior
cell fates [98,99]. During wnt signaling in C. elegans
L-catenin cooperates with the TAK1/NLK kinases to
downregulate TCFs activity as a repressor. It will be
of interest to further analyze the physiological role of
this pathway in mammalian development and cancer.
3. The ON state of the wnt pathway
Central to the transmission of the wnt signal is the
inhibition of GSK3L that results in the functional
inactivation of the L-catenin destruction complex.
The subsequent activation of wnt target genes is
then mediated by TCF/L-catenin complexes.
3.1. Dishevelled
Genetic epistasis experiments in Drosophila suggest
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that the inhibition of GSK3L function is mediated by
the cytoplasmic protein dishevelled. Ectopic expres-
sion of dishevelled mimics wnt signals in Drosophila
and Xenopus systems [101,102]. In mammalian cell
culture, overexpression of dishevelled inhibits the
catalytic activity of GSK3L [103] and stimulates
TCF-dependent reporter gene activity [80]. While
dishevelled appears to lack enzymatic function, it
contains potential interaction motifs found in signal
transduction components of other pathways (for re-
view see [104]), namely an N-terminal DIX domain
(found in dishevelled and axin), a central PDZ do-
main, and a C-terminal DEP domain (dishevelled,
egl-10 and pleckstrin). Both the DIX and PDZ do-
mains were shown to be required for the stabilization
of L-catenin in Drosophila cell lines [102], while the
DEP domain appears to be necessary for an alterna-
tive wnt-dependent ‘planar cell polarity’ pathway in-
volving Rho and Jnk [105]. How dishevelled is acti-
vated by frizzled is unknown, but dishevelled is
hyperphosphorylated upon wnt stimulation. Hyper-
phosphorylation correlates with the stabilization of
L-catenin. However, the overexpression of Drosophila
frizzled2 in the absence of ligands also results in hy-
perphosphorylation of dishevelled, but does not af-
fect L-catenin levels [102,106]. Maybe several kinases
are involved in the activation of dishevelled.
3.2. Dishevelled interacts with casein kinase IO
(CKIO)
CKIO can bind to the PDZ domain of dishevelled
and the overexpression of CKIO results in increased
phosphorylation of dishevelled. In cultured cells,
CKIO can be coprecipitated with dishevelled, axin,
and GSK3L. The CKI family consists of seven family
members in mammals and the N and O isoforms are
distinguished by an additional C-terminal domain
not found in the other members. This C-terminal
domain appears to be important in wnt signaling,
as CKIO lacking the C-terminal domain does not
coprecipitate with components of the destruction
complex [107,108]
Overexpression of CKIO mimics wnt signaling in a
variety of assays. In Xenopus embryos, ventral injec-
tion of CKIO induces a secondary axis, while mutants
lacking kinase activity or the C-terminal domain do
not. CKIO, like wnt, also rescues UV ventralized em-
bryos. CKIO induces wnt target genes, including sia-
mois and nodal-related 3, and low levels of both
Xwnt-8 and CKIO synergistically activate these genes.
In mammalian cells CKIO also activates a TCF-de-
pendent reporter gene. These activities of CKI corre-
late with increased L-catenin levels [107,108].
Interference with CKIO is also consistent with a
role in the wnt pathway. In Xenopus, dominant neg-
ative forms, as well as pharmacological inhibitors,
prevent the formation of a wnt-induced secondary
axis. Inhibition of CKI also blocks dishevelled-in-
duced secondary axis formation, but does not inhibit
the e¡ect of injected L-catenin. In C. elegans, RNAi
with the close homolog kin-19 mimics loss of func-
tion of wnt. In mammalian cells, a kinase-dead
CKIO, or CKIO antisense oligonucleotides inhibit
the wnt-induced TCF-dependent reporter gene activ-
ity [107,108]. Further epistasis experiments place
CKIO downstream of wnt, frizzled and dishevelled
and upstream of GSK3L and L-catenin, suggesting
that CKIO is involved in the dishevelled-mediated
inhibition of the L-catenin destruction complex. Ca-
sein kinase-2 (CK2) has also been shown to phos-
phorylate dishevelled, but is not su⁄cient for the
activation of dishevelled and downstream events
[106].
3.3. Dishevelled interacts with axin
Two domains of dishevelled required for transmis-
sion of the wnt signal have been shown to directly
interact with axin (Fig. 2) [67,109]. The N-terminal
200 amino acids (aa) of dishevelled, including the
DIX domain, interact with the C-terminal 105 aa
of axin that also include its DIX domain. In addi-
tion, the PDZ domain of dishevelled interacts with
the amino-terminal region of axin [109]. A C-termi-
nal fragment of axin containing little more than the
DIX domain inhibits the wnt-induced activation of a
TCF-dependent reporter, probably by interfering
with the axin/dishevelled interaction [109]. This sug-
gests that dishevelled blocks axin function by direct
interaction. Indeed, high concentrations of recombi-
nant dishevelled can inhibit the axin-mediated phos-
phorylation of L-catenin by GSK3L in vitro [67]. The
mechanism of inhibition is not understood, but it is
dependent on the PDZ domain of dishevelled. Fur-
ther, dishevelled does not compete with GSK3L for
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binding to axin [67] nor does it inhibit the catalytic
activity of GSK3L toward a synthetic peptide sub-
strate [110]. It is possible that dishevelled alters the
conformation of axin such that the accessibility of
L-catenin for GSK3L is reduced.
3.4. GBP/Frat1 can bind and inhibit GSK3L
An alternative mechanism for the inactivation of
GSK3L by dishevelled was suggested by the isolation
of the Xenopus GSK3L binding protein GBP. Over-
expression of GBP blocks the activity of GSK3L in
Xenopus embryos and leads to axis duplication, while
antisense interference with endogenous GBP prevents
axis formation [111]. GBP is closely related to a
mouse protooncogene Frat1 (frequently rearranged
in advanced T-cell lymphoma), which was indepen-
dently isolated as an oncogene in lymphocytes [112].
In mammalian cells the overexpression of Frat1 can
activate a TCF reporter gene [109]. While the C-ter-
minus of Frat1 binds to GSK3L, the N-terminus of
Frat1 has been shown to bind the PDZ domain of
dishevelled. Overexpression of a Frat1 fragment in-
cluding the dishevelled binding domain inhibits wnt-
induced TCF reporter gene activity, suggesting that
the dishevelled/Frat1 interaction is necessary for wnt
signaling. Since Frat1 is also found in a complex
with axin, it might be involved in the transmission
of the signal from dishevelled to the L-catenin de-
struction complex. In the presence of wnt, Frat1
and GSK3L have been observed to dissociate from
dishevelled and axin [109].
3.5. Role of PKC in the inactivation of GSK3L
Wnt-mediated inactivation of GSK3L seems to re-
quire the activity of a protein kinase C (PKC). Acti-
vation of PKC with TPA leads to inactivation of
GSK3L in the absence of a wnt signal and down-
regulation of PKC by prolonged treatment with
TPA prevents wnt-mediated inactivation of GSK3L
[113]. In vitro, several PKC isoforms can phosphor-
ylate and inactivate GSK3L [114]. Overexpression of
PKCLII in the colonic epithelium of mice results in
hyperproliferation of intestinal epithelial cells and
increased sensitivity to carcinogen-induced colon
cancer, which could be due to aberrant activation
of the wnt pathway. Consistent with this idea, the
colonic epithelium of PKCbII transgenic mice shows
reduced GSK3L activity and elevated L-catenin levels
[115].
3.6. Dissociation of the L-catenin destruction complex
Once the action of GSK3L is restrained, L-catenin
becomes dephosphorylated and invisible for slimb/
LTrCP and the ubiquitination machinery. However,
to interact with downstream components of the wnt
pathway, it must also be released from axin/conduc-
tin and APC. Apparently, the inhibition of GSK3L
has fatal consequences for the destruction complex
that promote the release of L-catenin.
In the absence of wnt signals, GSK3L not only
phosphorylates L-catenin, but also axin [57,110,
116]. Upon wnt stimulation or inhibition of GSK3L
with LiCl, axin is dephosphorylated [110,116]. De-
phosphorylation of axin may cause the release of
L-catenin from the destruction complex by two
means. First, the a⁄nity of hypophosphorylated
axin toward L-catenin is reduced: beads coated
with L-catenin precipitate only the phosphorylated
form of axin from cell extracts. Conversely, immobi-
lized recombinant axin precipitates more cellular
L-catenin, when axin is ¢rst in vitro phosphorylated
by GSK3L [116]. Second, the hypophosphorylated
axin protein is unstable: prolonged stimulation
with wnt, or treatment with LiCl, decreases the cel-
lular levels of axin protein, while the phosphatase
inhibitor okadaic acid stabilizes axin [110,116].
Axin also stimulates the phosphorylation of APC
by GSK3L [56,68], and GSK3L has been shown to
phosphorylate APC within the central 20 aa repeat
region [117]. All seven 20 aa repeats contain an
SXXXS(P) motif, which is likely to be the target
for GSK3L. The 20 aa repeats bind L-catenin, and
phosphorylation of this region by GSK3L in vitro
has been shown to enhance the binding to L-catenin
[117]. As suggested for axin, wnt signals might result
in the dephosphorylation of APC resulting in its dis-
sociation from L-catenin. There is also some evidence
to suggest that catalytically inactive GSK3L is also
excluded from the destruction complex. Axin, APC
and L-catenin coprecipitate with wild-type, but not
with kinase-dead GSK3L [57,117]. Taken together,
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these data suggest that the integrity of the destruc-
tion complex depends on GSK3L-dependent phos-
phorylation events and that inhibition of GSK3L
function causes a dissociation of the destruction
complex by decreasing the a⁄nity of the components
for one another.
It is likely that a rapid response to wnt signals
requires the action of phosphatases that reverse the
GSK3L-mediated phosphorylation steps. The cata-
lytic subunit of protein phosphatase 2A (PP2A) can
bind to and dephosphorylate axin [65,116] and the
phosphatase inhibitor okadaic acid prevents wnt-in-
duced dephosphorylation of axin [116]. The PP2A
regulatory subunit B56 binds to APC, and when
overexpressed, reduces L-catenin levels and inhibits
target gene transcription [118]. It is presently un-
clear whether overexpression of B56 stimulates or
prevents the dephosphorylation of signaling compo-
nents. It is intriguing that mutations of the PP2A A
subunit have been identi¢ed in colon and lung can-
cers [119].
3.7. Nuclear translocation of L-catenin
Inactivation of the L-catenin destruction complex
leads to the cytosolic accumulation and subsequent
nuclear translocation of L-catenin. L-Catenin lacks
an obvious nuclear localization sequence (NLS) for
importin K/L receptors, and two distinct mechanisms
for the translocation process have been proposed.
First, free L-catenin might ‘piggy-back’ into the nu-
cleus bound to newly synthesized or shuttling TCFs
[120^123]. Alternatively, L-catenin may enter the nu-
cleus independently of TCFs. Mutant forms of L-cat-
enin unable to bind to TCF can still translocate to
the nucleus [21,124]. Moreover, L-catenin was able to
enter the nucleus in an in vitro nuclear import assay.
Translocation of L-catenin was independent of im-
portins, mimicking the behavior of importin L in
such assays [125,126]. It is unclear whether the nu-
clear translocation of L-catenin is a default conse-
quence of its cytosolic accumulation, or further regu-
lated by wnt signals. Of interest in this respect is the
interaction of L-catenin with the presenilins, which
are proteins altered in Alzheimer’s disease. It has
been suggested that presenilins are involved in the
nuclear translocation of L-catenin upon wnt signal-
ing [127].
3.8. Activation of transcription
TCFs are sequence-speci¢c DNA binding proteins,
but apparently have no classical transactivation do-
main on their own. In immune cells LEF-1 appears
to act as context-dependent transcriptional activator
that requires cooperativity with neighboring tran-
scription factors [128,129]. Apparently two distinct
mechanisms are involved in the activation of wnt
target genes by TCF/L-catenin complexes and there
is evidence that both mechanisms may operate dur-
ing wnt signaling [25]. First, TCFs can behave as
active repressors of gene expression and wnt signal-
ing relieves this repression. Second, TCFs can behave
as ‘silent’ transcription factors that activate gene
transcription upon binding to L-catenin. Collectively
the data suggest that TCFs mediate repression of
target genes in the absence of wnt signaling, while
acting as transcriptional activators in the presence of
wnt.
There is genetic evidence that wnt signaling results
in de-repression of TCF-mediated transcription. In
transgenic £ies, the addition of TCF binding sites
to a minimal synthetic promoter stimulates expres-
sion in cells that receive a wnt signal, but reduces
expression in cells that do not [130]. In Xenopus,
TCF/L-catenin complexes are active only in the dor-
sal part of the embryo and locally activate siamois
expression. Elimination of the three TCF binding
sites in the siamois promoter results in reduced dor-
sal, but increased ventral expression of the gene
[131].
As described above, TCFs may repress gene ex-
pression by binding to transcriptional co-repressors
such as TLE/groucho or CtBP. It is not clear how
L-catenin interferes with TLE/groucho-mediated re-
pression of target genes. The binding sites in TCFs of
TLE/groucho and L-catenin do not overlap which
rules out direct competition of both factors [132].
As discussed above, CBP antagonizes wingless sig-
naling by acetylating dTCF at its armadillo binding
domain. Binding of armadillo to dTCF has been
shown to reduce the ability of CBP to catalyze this
reaction, perhaps by steric interference [97].
If TCFs acted solely as repressors, their loss-of-
function phenotypes should mimic activated wnt sig-
naling; however, loss of TCF function in Drosophila
and Xenopus mimics loss of function of wnt or L-cat-
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enin [120^122,130,133,134]. This suggests a positive
role for TCFs as transcriptional activators during
wnt signaling. Transcriptional activation depends
on the binding of TCF to L-catenin. Reporter con-
structs containing TCF binding sites could be acti-
vated by coexpression of TCF and L-catenin, but not
by TCF alone [122]. Genetic experiments show that
the C-terminal domain of armadillo is indispensable
for wingless signaling [77] and both C- and N-termi-
nal regions of L-catenin have been shown to provide
transactivation domains. For instance, fusion pro-
teins of the N- or C-terminal domains of L-catenin
with the Gal4 DNA binding domains activate Gal4
responsive promoter constructs [133,135,136]. Fusion
proteins of LEF-1 with the C-terminal domain of
L-catenin, or with the potent VP16 transactivation
domain activate LEF-1 dependent promoters to a
similar extent [137]. Moreover both fusion proteins
induce axis duplication in Xenopus indicating that
the transactivation function of L-catenin is su⁄cient
for wnt signaling in this particular experimental set-
ting. Similarly, cell transformation of chicken em-
bryo ¢broblasts could be achieved by expression of
chimeras of LEF-1 and various heterologous trans-
activation domains [52]. TCF/L-catenin complexes
can thus be regarded as bipartite transcription fac-
tors in which the DNA binding and transactivation
functions are contributed by two separate proteins.
How the transactivation domains of L-catenin ac-
tivate transcription is presently unclear but associa-
tions of L-catenin with the TATA binding protein
(TBP) have been shown [136]. In addition L-catenin
might contact TBP indirectly via binding to Pontin52
[138]. This indicates that TCF/L-catenin complexes
directly recruit components of the basal transcrip-
tional machinery to wnt target genes. Interestingly,
expression of LEF-1 and L-catenin in normal T cells
was not su⁄cient to activate reporter gene transcrip-
tion suggesting that LEF-1/L-catenin require addi-
tional factors not present in these cells [124].
3.9. Wnt target genes
Several genes whose expression is regulated by
TCF/L-catenin complexes have been described. The
c-myc gene was shown to be downregulated by con-
ditional expression of APC in a colorectal cancer cell
line. The c-myc promoter contains TCF binding sites
which mediate transcriptional activation by TCF/L-
catenin as well as repression by APC in reporter gene
assays. A dominant-negative version of TCF-4 re-
duced endogenous levels of c-myc, indicating that
TCF/L-catenin complexes are essential regulators of
the c-myc gene in colorectal cancer cells [50,139]. The
cyclinD1 promoter also contains TCF binding sites
and is activated by L-catenin; importantly, domi-
nant-negative TCF causes arrest of colon cancer cells
in the G1 phase of the cell cycle, which can be res-
cued by expression of cyclinD1 [51]. Further targets
for L-catenin signaling with relevance for tumor de-
velopment have been identi¢ed, such as components
of the AP-1 complex and the extracellular matrix
protease matrilysin [140,141]. Genes involved in de-
velopmental aspects of wnt signaling, such as siamois
[131], ultrabithorax [130], nodal-related 3 [142], and
twin [143] are direct targets of TCF/L-catenin com-
plexes. The promoters of these genes contain TCF
binding sites which are essential for transcriptional
activation as demonstrated by mutational analysis.
Given the multiple activities of wnts it is certain
that the list of target genes will increase in the future.
4. Conclusions and perspectives
Signi¢cant progress has been made over the years
in understanding the biochemical mechanisms that
regulate the wnt pathway. This has been paralleled
by the analysis of the in vivo function of key signal-
ing components. Important questions remain to be
answered. For instance, our knowledge of the reper-
toire of direct target genes of wnt signaling is still
limited. Given the importance of the pathway in
both normal development and cancer it is likely
that e¡orts will be made to discover new TCF/L-cat-
enin target genes. As seen in other ¢elds of signal
transduction research, the wnt cascade might be
part of a larger network of signaling systems. Several
components such as GSK3L and factors of the ubiq-
uitination machinery appear to be regulated by stim-
uli di¡erent from wnt and might represent entry
points for cross-talk to other systems. The interest
in the wnt signaling pathway has been nourished
by the ¢nding of its oncogenic relevance. It is ob-
vious that interference with the pathway in tumors
could be of therapeutic value in anticancer treatment.
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Drugs might be searched for that block the interac-
tion of TCFs and L-catenin, or prevent transcription-
al activation by the complex. In addition, when more
is known about the biochemical mechanisms that
regulate L-catenin stability, it might become possible
to devise strategies that enhance the degradation of
L-catenin and thereby block its accumulation in tu-
mor cells.
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